AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) title “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC).
To hear the NetworkNewsAudio version, visit https://nnw.fm/kSRbS
To read the original editorial, visit https://nnw.fm/rbsvJ
Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting to delivery-optimizing, companies that control best-in-class bioavailability engines are positioned to redefine the competitive landscape.
Oncotelic Therapeutics’ Deciparticle(TM) technology directly addresses this effective drug-delivery need with a modular, ultra-high-efficiency nanomedicine delivery engine. The platform is designed to elevate drug bioavailability from conventional 10–20% to potentially 80–100% in preclinical models. Rather than inventing entirely new drug molecules, Deciparticle(TM) focuses on re-engineering the way existing and emerging drugs are delivered into the body, maximizing their performance without requiring molecular redesign.
About Oncotelic Therapeutics Inc.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 500 patent applications with 75 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.
For further information, please visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: www.NetworkNewsAudio.com
NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
